FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 141 filers reported holding FIVE PRIME THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 5.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $614,000 | -29.7% | 15,000 | -48.3% | 0.02% | -37.8% |
Q2 2017 | $873,000 | -19.5% | 29,000 | -3.3% | 0.04% | -14.0% |
Q1 2017 | $1,085,000 | -22.7% | 30,000 | +7.1% | 0.04% | -36.8% |
Q4 2016 | $1,403,000 | -4.6% | 28,000 | 0.0% | 0.07% | -25.3% |
Q3 2016 | $1,470,000 | +21.9% | 28,000 | -4.0% | 0.09% | -2.2% |
Q2 2016 | $1,206,000 | -25.8% | 29,160 | -27.1% | 0.09% | +31.0% |
Q1 2016 | $1,625,000 | -28.8% | 40,000 | -27.3% | 0.07% | -54.8% |
Q4 2015 | $2,283,000 | +128.3% | 55,000 | -15.4% | 0.16% | +256.8% |
Q3 2015 | $1,000,000 | -19.5% | 65,000 | +30.0% | 0.04% | -10.2% |
Q2 2015 | $1,242,000 | -6.3% | 50,000 | -13.8% | 0.05% | -16.9% |
Q1 2015 | $1,325,000 | -29.9% | 58,000 | -17.1% | 0.06% | -9.2% |
Q4 2014 | $1,890,000 | +79.0% | 70,000 | -22.2% | 0.06% | +150.0% |
Q3 2014 | $1,056,000 | -9.4% | 90,000 | +20.0% | 0.03% | +4.0% |
Q2 2014 | $1,166,000 | -30.2% | 75,000 | -11.8% | 0.02% | -26.5% |
Q1 2014 | $1,671,000 | – | 85,000 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 115,500 | $2,531,000 | 0.89% |
AWM Investment Company, Inc. | 150,000 | $3,288,000 | 0.64% |
BB BIOTECH AG | 827,500 | $18,139,000 | 0.51% |
Virtus ETF Advisers LLC | 17,371 | $381,000 | 0.48% |
Rock Springs Capital Management LP | 425,000 | $9,316,000 | 0.42% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,728 | $9,880,000 | 0.39% |
Telemetry Investments, L.L.C. | 44,176 | $968,000 | 0.37% |
RTW INVESTMENTS, LP | 100,377 | $2,200,000 | 0.37% |
Eventide Asset Management | 315,000 | $6,905,000 | 0.36% |
ACUTA CAPITAL PARTNERS, LLC | 52,500 | $1,151,000 | 0.22% |